Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals will host a conference call on June 13, 2026, to present interim six-month results from its Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome. The data presentation will be led by CEO David Meeker and Dr. Jennifer Miller from the University of Florida College of Medicine.
Key figures
- Drug Name
- setmelanotide
- Phase Of Trial
- Phase 2
- Indication
- Prader-Willi syndrome
- Trial duration
- six-month
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.